TITLE

Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival

AUTHOR(S)
Canet, Emmanuel; Zafrani, Lara; Lambert, Jerome; Thieblemont, Catherine; Galicier, Lionel; Schnell, David; Raffoux, Emmanuel; Lengline, Etienne; Chevret, Sylvie; Darmon, Michael; Azoulay, Elie
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Optimal chemotherapy with minimal toxicity is the main determinant of complete remission in patients with newly diagnosed hematological malignancies. Acute organ dysfunctions may impair the patient’s ability to receive optimal chemotherapy. Design and Methods: To compare 6-month complete remission rates in patients with and without acute kidney injury (AKI), we collected prospective data on 200 patients with newly diagnosed high-grade malignancies (non-Hodgkin lymphoma, 53.5%; acute myeloid leukemia, 29%; acute lymphoblastic leukemia, 11.5%; and Hodgkin disease, 6%). Results: According to RIFLE criteria, 137 (68.5%) patients had AKI. Five causes of AKI accounted for 91.4% of cases: hypoperfusion, tumor lysis syndrome, tubular necrosis, nephrotoxic agents, and hemophagocytic lymphohistiocytosis. Half of the AKI patients received renal replacement therapy and 14.6% received suboptimal chemotherapy. AKI was associated with a lower 6-month complete remission rate (39.4% vs. 68.3%, P<0.01) and a higher mortality rate (47.4% vs. 30.2%, P<0.01) than patients without AKI. By multivariate analysis, independent determinants of 6-month complete remission were older age, poor performance status, number of organ dysfunctions, and AKI. Conclusion: AKI is common in patients with newly diagnosed high-grade malignancies and is associated with lower complete remission rates and higher mortality.
ACCESSION #
87624070

 

Related Articles

  • Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. DAN YANG; XIAORUI FU; XUDONG ZHANG; WENCAI LI; MINGZHI ZHANG // Oncology Letters;Nov2015, Vol. 10 Issue 5, p3261 

    Due to advances in the treatment of lymphoma, the remission and overall survival rates for this disease have improved in recent years. However, the incidence of therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) has increased. In order to further the understanding of the...

  • Landmark analysis of DNMT3A mutations in hematological malignancies. Roller, A; Grossmann, V; Bacher, U; Poetzinger, F; Weissmann, S; Nadarajah, N; Boeck, L; Kern, W; Haferlach, C; Schnittger, S; Haferlach, T; Kohlmann, A // Leukemia (08876924);Jul2013, Vol. 27 Issue 7, p1573 

    The article presents a study that analyzes the DNMT3A mutations in hematological malignancies. It explores the method of the study that observes DNMT3Amut in mutation frequencies in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. The result of the...

  • Treat Large AMLs Electively to Prevent Complications.  // Kidney;Nov/Dec98, Vol. 7 Issue 6, p251 

    Presents an abstract of the study 'Treat Large AMLs Electively to Prevent Complications,' by M. Dickinson et al published in a 1998 issue of 'Clinical Nephrology.'

  • T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Cantwell, M J; Wierda, W G; Lossos, I S; Levy, R; Kipps, T J // Leukemia (08876924);Sep2001, Vol. 15 Issue 9, p1451 

    Purified, high-titer adenovirus encoding murine CD154 (Ad-CD154) or human CD154 (Ad-hCD154) was used to infect lymph node cells isolated from patients with follicle center lymphoma. Infection of lymphoma B cells with Ad-CD154 at a multiplicity of infection (MOI) ratio of 100 or higher resulted...

  • CD40 ligation reverses T cell tolerance in acute myeloid leukemia. Long Zhang; Xiufen Chen; Xiao Liu; Kline, Douglas E.; Teague, Ryan M.; Gajewski, Thomas F.; Kline, Justin // Journal of Clinical Investigation;May2013, Vol. 123 Issue 5, p1999 

    Spontaneous antigen-specific T cell responses can be generated in hosts harboring a variety of solid malignancies, but are subverted by immune evasion mechanisms active within the tumor microenvironment. In contrast to solid tumors, the mechanisms that regulate T cell activation versus tolerance...

  • Granulocytic Sarcoma. Goldstein, Neal S.; Ritter, Jon H.; Argenyi, Zsolt B.; Wick, Mark R. // International Journal of Surgical Pathology;Jan1995, Vol. 2 Issue 3, p177 

    Because of shared histologic and clinical features, granulocytic sarcoma (GS) may be confused with B- and T cell malignant lymphomas. Antibodies to myeloperoxidase, lysozyme, CD 15, and other determinants may correctly identity GS but are usually not part of the standard panels employed to...

  • CME/SAM.  // American Journal of Clinical Pathology;Aug2014, Vol. 142 Issue 2, p273 

    A Continuing Medical Education activity which qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module on several topics is presented, including the differential diagnosis of B-cell lymphomas, the relationship between rhinovirus species and the...

  • Successful Surgical Intervention in An Unusual Case of Aspergillus Endocarditis with Acute Myeloid Leukemia. Aval, Zahra Ansari; Mirhosseini, Seyed Mohsen; Fakhri, Mohammad; Mozaffary, Amirhossein; Naghan, Parisa Adimi; Behzadnia, Neda; Ahmadi, Zargham-Hossein // Acta Medica Iranica;2013, Vol. 51 Issue 7, p506 

    Endocarditis due to Aspergillus infection is a rare complication in patients with hematological malignancies. Here, we present a case of aspergillus endocarditis in a patient with acute myeloid leukemia (AML) successfully treated with antifungal therapy and surgical treatment. The patient was a...

  • Homoharringtonine and omacetaxine for myeloid hematological malignancies. Shuqing Lü; Jianmin Wang // Journal of Hematology & Oncology;2014, Vol. 7 Issue 1, p2 

    Homoharringtonine (HHT), a plant alkaloid with antitumor properties originally identified nearly 40 years ago, has a unique mechanism of action by preventing the initial elongation step of protein synthesis. HHT has been used widely in China for the treatment of chronic myeloid leukemia (CML),...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics